Emergent BioSolutions, Inc. (NYSE: EBS)

This investigation is for anyone who acquired securities in Emergent BioSolutions, Inc. (NYSE: EBS) prior to August 5, 2026.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by downplaying competitive headwinds facing the Company.

On August 5, 2026, Emergent reported results for the quarter ended June 30, 2026. Among other items, Emergent announced, among other things, a $191.3 million non-cash impairment charge on the NARCAN asset group, driving a GAAP net loss of $180.2 million. The Company also cut full year revenue guidance approximately 10.8% at the midpoint. Management attributed its results to “increased competitive intensity with implications for our near to medium term outlook and the book value of our NARCAN asset group” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Emergent BioSolutions, Inc. (NYSE: EBS) prior to August 5, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.